Conference Coverage

Experimental PD-1/PARP inhibitor combo shows promise in solid tumors

Publish date: January 26, 2018

 

REPORTING FROM THE CLINICAL IMMUNO-ONCOLOGY SYMPOSIUM

SOURCE: Friedlander M et al. ASCO-SITC Clinical Immuno-Oncology Symposium 2018, Abstract #48.

Pages

Recommended Reading

Strategies to evaluate postmenopausal bleeding
MDedge Hematology and Oncology
Morphology index guides adnexal mass workup in postmenopausal women
MDedge Hematology and Oncology
NCI-MATCH: Nivolumab shows promising activity in noncolorectal cancers
MDedge Hematology and Oncology
Real-world data support extended cervical cancer screening interval
MDedge Hematology and Oncology
Complex atypical hyperplasia: When is it appropriate to refer?
MDedge Hematology and Oncology
Pembrolizumab for dMMR/MSI-H tumors marks first tumor agnostic FDA approval
MDedge Hematology and Oncology
FDA: Laparoscopic power morcellators can spread malignant cells when used in women with occult uterine cancers*
MDedge Hematology and Oncology
Age at RRSO affects peritoneal cancer risk in BRCA mutation carriers
MDedge Hematology and Oncology
HIPEC shows survival benefit for advanced ovarian cancer
MDedge Hematology and Oncology
New multi-analyte blood test shows promise in screening for several common solid tumors
MDedge Hematology and Oncology